Trade Agios Pharmaceuticals, Inc. - AGIO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading Conditions
| Long position overnight fee | -0.0225% |
| Short position overnight fee | -0.0219% |
| Overnight fee time | 21:00 (UTC) |
| Min traded quantity | 1 |
| Currency | USD |
| Margin | 20% |
| Stock exchange | United States of America |
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 25.94 |
| Open* | 26.67 |
| Day's Range* | 26.57 - 26.57 |
| 1-Year Change* | -38.87% |
| Volume | N/A |
| Average Vol. (3m) | 15.0863 |
| 52 wk Range | N/A |
| Market Cap | 1546.96 |
| P/E Ratio | N/A |
| Shares Outstanding | 54818000 |
| Revenue | 6.414 |
| EPS | -6.70569 |
| Dividend (Yield %) | N/A |
| Beta | 1.2398 |
| Next Earnings Date | Nov 1, 2022 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Aug 11, 2022 | 25.94 | -2.28 | -8.08% | 28.22 | 28.23 | 25.72 |
| Aug 10, 2022 | 28.15 | 1.19 | 4.41% | 26.96 | 28.31 | 26.92 |
| Aug 9, 2022 | 27.32 | -1.02 | -3.60% | 28.34 | 28.89 | 27.03 |
| Aug 8, 2022 | 29.31 | 0.79 | 2.77% | 28.52 | 29.45 | 28.09 |
| Aug 5, 2022 | 29.67 | 2.18 | 7.93% | 27.49 | 29.97 | 27.02 |
| Aug 4, 2022 | 28.56 | 3.31 | 13.11% | 25.25 | 28.57 | 24.98 |
| Aug 3, 2022 | 24.85 | 2.00 | 8.75% | 22.85 | 24.91 | 22.85 |
| Aug 2, 2022 | 22.88 | 2.02 | 9.68% | 20.86 | 23.23 | 20.86 |
| Aug 1, 2022 | 21.23 | 0.28 | 1.34% | 20.95 | 21.74 | 20.87 |
| Jul 29, 2022 | 21.51 | 0.54 | 2.58% | 20.97 | 21.56 | 20.71 |
| Jul 28, 2022 | 21.49 | 0.12 | 0.56% | 21.37 | 21.79 | 20.80 |
| Jul 27, 2022 | 21.55 | 1.00 | 4.87% | 20.55 | 21.66 | 20.36 |
| Jul 26, 2022 | 19.45 | -0.02 | -0.10% | 19.47 | 20.28 | 19.37 |
| Jul 25, 2022 | 19.94 | -0.52 | -2.54% | 20.46 | 20.47 | 19.74 |
| Jul 22, 2022 | 20.46 | -1.24 | -5.71% | 21.70 | 21.94 | 20.32 |
| Jul 21, 2022 | 21.76 | 0.00 | 0.00% | 21.76 | 21.88 | 21.44 |
| Jul 20, 2022 | 21.81 | 0.18 | 0.83% | 21.63 | 22.40 | 21.47 |
| Jul 19, 2022 | 21.56 | 0.42 | 1.99% | 21.14 | 21.83 | 21.00 |
| Jul 18, 2022 | 20.94 | -1.39 | -6.22% | 22.33 | 22.89 | 20.83 |
| Jul 15, 2022 | 22.25 | -0.81 | -3.51% | 23.06 | 23.06 | 21.67 |
Agios Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, November 1, 2022 | ||
| 12:30 | | Q3 2022 Agios Pharmaceuticals Inc Earnings Release |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 69.892 | 43.011 | 94.387 | 0 | 0 | 0 |
| Revenue | 69.892 | 43.011 | 94.387 | |||
| Total Operating Expense | 270.877 | 363.805 | 456.866 | 316.269 | 335.916 | 371.779 |
| Selling/General/Admin. Expenses, Total | 50.714 | 71.124 | 114.145 | 102.007 | 115.105 | 121.445 |
| Research & Development | 220.163 | 292.681 | 341.324 | 214.262 | 220.811 | 256.973 |
| Operating Income | -200.985 | -320.794 | -362.479 | -316.269 | -335.916 | -371.779 |
| Interest Income (Expense), Net Non-Operating | 2.514 | 6.124 | 16.451 | 14.861 | 6.611 | 0.836 |
| Net Income Before Taxes | -198.471 | -314.67 | -346.028 | -301.408 | -329.305 | -356.51 |
| Net Income After Taxes | -198.471 | -314.67 | -346.028 | -301.408 | -329.305 | -356.51 |
| Net Income Before Extra. Items | -198.471 | -314.67 | -346.028 | -301.408 | -329.305 | -356.51 |
| Net Income | -198.471 | -314.67 | -346.028 | -411.472 | -327.37 | 1604.71 |
| Total Adjustments to Net Income | 0 | |||||
| Income Available to Common Excl. Extra. Items | -198.471 | -314.67 | -346.028 | -301.408 | -329.305 | -356.51 |
| Income Available to Common Incl. Extra. Items | -198.471 | -314.67 | -346.028 | -411.472 | -327.37 | 1604.71 |
| Diluted Net Income | -198.471 | -314.67 | -346.028 | -411.472 | -327.37 | 1604.71 |
| Diluted Weighted Average Shares | 39.1264 | 46.5876 | 57.4183 | 59.9945 | 68.9979 | 60.4473 |
| Diluted EPS Excluding Extraordinary Items | -5.07256 | -6.75437 | -6.02644 | -5.02392 | -4.77268 | -5.89786 |
| Dividends per Share - Common Stock Primary Issue | 0 | |||||
| Diluted Normalized EPS | -5.07256 | -6.75437 | -6.02644 | -5.02392 | -4.77268 | -6.00769 |
| Total Extraordinary Items | 0 | -110.064 | 1.935 | 1961.22 | ||
| Cost of Revenue, Total | 1.397 | |||||
| Gross Profit | 92.99 | |||||
| Unusual Expense (Income) | 0 | 0 | -6.639 | |||
| Other, Net | 0 | 0 | 14.433 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0.832 |
| Total Operating Expense | 91.217 | 89.222 | 89.156 | 102.184 | 99.273 |
| Selling/General/Admin. Expenses, Total | 33.55 | 29.215 | 27.152 | 31.528 | 31.515 |
| Research & Development | 57.667 | 62.007 | 64 | 73.299 | 70.123 |
| Operating Income | -91.217 | -89.222 | -89.156 | -102.184 | -98.441 |
| Interest Income (Expense), Net Non-Operating | 0.34 | -0.092 | 0.256 | 0.332 | 0.694 |
| Net Income Before Taxes | -90.877 | -82.79 | -84.259 | -98.584 | -94.774 |
| Net Income After Taxes | -90.877 | -82.79 | -84.259 | -98.584 | -94.774 |
| Net Income Before Extra. Items | -90.877 | -82.79 | -84.259 | -98.584 | -94.774 |
| Total Extraordinary Items | 1965.2 | -3.427 | -4.507 | 3.957 | 0 |
| Net Income | 1874.32 | -86.217 | -88.766 | -94.627 | -94.774 |
| Income Available to Common Excl. Extra. Items | -90.877 | -82.79 | -84.259 | -98.584 | -94.774 |
| Income Available to Common Incl. Extra. Items | 1874.32 | -86.217 | -88.766 | -94.627 | -94.774 |
| Diluted Net Income | 1874.32 | -86.217 | -88.766 | -94.627 | -94.774 |
| Diluted Weighted Average Shares | 69.5435 | 61.067 | 57.0482 | 54.2801 | 54.5555 |
| Diluted EPS Excluding Extraordinary Items | -1.30676 | -1.35572 | -1.47698 | -1.81621 | -1.7372 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.30676 | -1.38848 | -1.51197 | -1.8649 | -1.78677 |
| Unusual Expense (Income) | -2 | -1.996 | -2.643 | -2.704 | |
| Other, Net | 6.524 | 4.641 | 3.268 | 2.973 | |
| Revenue | 0.832 | ||||
| Cost of Revenue, Total | 0.339 | ||||
| Gross Profit | 0.493 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 559.892 | 445.261 | 613.78 | 611.704 | 636.677 | 1064.23 |
| Cash and Short Term Investments | 541.314 | 423.936 | 585.302 | 564.877 | 572.929 | 1020.02 |
| Cash & Equivalents | 160.754 | 102.724 | 70.502 | 80.931 | 127.436 | 203.126 |
| Short Term Investments | 380.56 | 321.212 | 514.8 | 483.946 | 445.493 | 816.892 |
| Total Receivables, Net | 8.314 | 3.839 | 10.442 | 15.319 | 25.399 | 4.378 |
| Prepaid Expenses | 10.264 | 17.486 | 17.167 | 24.177 | 23.651 | 39.835 |
| Total Assets | 619.094 | 614.397 | 858.457 | 890.741 | 852.952 | 1437.74 |
| Property/Plant/Equipment, Total - Net | 25.337 | 24.431 | 24.32 | 126.108 | 117.542 | 104.23 |
| Property/Plant/Equipment, Total - Gross | 38.709 | 43.828 | 50.472 | 158.22 | 158.895 | 149.204 |
| Accumulated Depreciation, Total | -13.372 | -19.397 | -26.152 | -32.112 | -41.353 | -44.974 |
| Long Term Investments | 32.25 | 143.814 | 220.119 | 152.929 | 97.608 | 266.375 |
| Other Long Term Assets, Total | 1.615 | 0.891 | 0.238 | 0 | 1.125 | 2.9 |
| Total Current Liabilities | 88.433 | 94.941 | 93.503 | 92.886 | 94.394 | 59.826 |
| Accounts Payable | 17.106 | 22.767 | 17.88 | 21.896 | 26.844 | 16.7 |
| Accrued Expenses | 32.002 | 34.031 | 42.147 | 59.784 | 67.233 | 42.795 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 39.325 | 38.143 | 33.476 | 10.933 | 0 | 0 |
| Total Liabilities | 260.503 | 238.894 | 170.92 | 250.213 | 453.452 | 145.761 |
| Total Long Term Debt | 0 | 0 | 0 | 0.673 | 0.331 | 0.276 |
| Other Liabilities, Total | 172.07 | 143.953 | 77.417 | 156.654 | 358.727 | 85.659 |
| Total Equity | 358.591 | 375.503 | 687.537 | 640.528 | 399.5 | 1291.97 |
| Common Stock | 0.042 | 0.049 | 0.058 | 0.068 | 0.069 | 0.071 |
| Additional Paid-In Capital | 842.013 | 1174.9 | 1794.28 | 2156.36 | 2242.8 | 2334.35 |
| Retained Earnings (Accumulated Deficit) | -483.151 | -798.061 | -1104.63 | -1516.1 | -1843.47 | -238.76 |
| Other Equity, Total | -0.313 | -1.389 | -2.171 | 0.202 | 0.105 | -1.198 |
| Total Liabilities & Shareholders’ Equity | 619.094 | 614.397 | 858.457 | 890.741 | 852.952 | 1437.74 |
| Total Common Shares Outstanding | 42.2204 | 48.8261 | 58.2187 | 68.4011 | 69.2939 | 54.3342 |
| Accounts Receivable - Trade, Net | 1.222 | 7.31 | 11.852 | 21.328 | ||
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 | |
| Total Inventory | 0.869 | 7.331 | 14.698 | |||
| Current Port. of LT Debt/Capital Leases | 0.273 | 0.317 | 0.331 | |||
| Capital Lease Obligations | 0.673 | 0.331 | 0.276 | |||
| Total Preferred Shares Outstanding | 0 | 0 | 0 | |||
| Other Current Assets, Total | 0 | |||||
| Treasury Stock - Common | -802.486 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2355.11 | 1702.56 | 1305.29 | 1064.23 | 975.145 |
| Cash and Short Term Investments | 2335.6 | 1672.99 | 1266.06 | 1020.02 | 923.529 |
| Cash & Equivalents | 1888.03 | 969.124 | 400.224 | 203.126 | 80.026 |
| Short Term Investments | 447.578 | 703.864 | 865.833 | 816.892 | 843.503 |
| Prepaid Expenses | 19.511 | 21.443 | 32.238 | 39.835 | 43.226 |
| Other Current Assets, Total | 0 | 0 | 0 | 0 | |
| Total Assets | 2488.43 | 1874.6 | 1541.5 | 1437.74 | 1335.86 |
| Property/Plant/Equipment, Total - Net | 111.722 | 107.828 | 103.174 | 104.23 | 101.978 |
| Long Term Investments | 21.598 | 61.313 | 130.139 | 266.375 | 255.836 |
| Other Long Term Assets, Total | 0 | 2.9 | 2.9 | 2.9 | 2.9 |
| Total Current Liabilities | 96.504 | 60.649 | 57.896 | 59.826 | 45.792 |
| Accounts Payable | 51.224 | 7.654 | 10.308 | 16.7 | 11.551 |
| Accrued Expenses | 31.589 | 44.986 | 39.117 | 42.795 | 31.491 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.321 | 0.839 | 0.412 | 0.331 | 0.25 |
| Other Current Liabilities, Total | 13.37 | 7.17 | 8.059 | 0 | 2.5 |
| Total Liabilities | 191.804 | 152.787 | 146.736 | 145.761 | 128.406 |
| Total Long Term Debt | 0.248 | 0.167 | 0 | 0.276 | 0.276 |
| Capital Lease Obligations | 0.248 | 0.167 | 0 | 0.276 | 0.276 |
| Other Liabilities, Total | 95.052 | 91.971 | 88.84 | 85.659 | 82.338 |
| Total Equity | 2296.63 | 1721.82 | 1394.76 | 1291.97 | 1207.45 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.07 | 0.07 | 0.071 | 0.071 | 0.071 |
| Additional Paid-In Capital | 2265.71 | 2306.3 | 2322.46 | 2334.35 | 2351.15 |
| Retained Earnings (Accumulated Deficit) | 30.85 | -55.367 | -144.133 | -238.76 | -333.534 |
| Other Equity, Total | -0.003 | -0.144 | -0.198 | -1.198 | -7.745 |
| Total Liabilities & Shareholders’ Equity | 2488.43 | 1874.6 | 1541.5 | 1437.74 | 1335.86 |
| Total Common Shares Outstanding | 69.8122 | 59.9108 | 54.7152 | 54.3342 | 54.7769 |
| Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
| Total Receivables, Net | 8.131 | 6.99 | 4.378 | 5.905 | |
| Treasury Stock - Common | -529.047 | -783.438 | -802.486 | -802.486 | |
| Accounts Receivable - Trade, Net | 0.54 | ||||
| Total Inventory | 2.485 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -198.471 | -314.67 | -346.028 | -411.472 | -327.37 | 1604.71 |
| Cash From Operating Activities | 38.562 | -285.232 | -304.421 | -370.622 | -290.759 | -407.32 |
| Cash From Operating Activities | 5.708 | 6.432 | 7.172 | 8.087 | 9.984 | 9.24 |
| Non-Cash Items | 42.859 | 47.838 | 69.54 | 78.762 | 97.664 | -1984.45 |
| Cash Taxes Paid | 0 | |||||
| Changes in Working Capital | 188.466 | -24.832 | -35.105 | -45.999 | -71.037 | -36.822 |
| Cash From Investing Activities | -119.35 | -57.908 | -273.825 | 91.44 | 75.746 | 1248.78 |
| Capital Expenditures | -9.915 | -4.627 | -6.986 | -12.171 | -14.909 | -5.741 |
| Other Investing Cash Flow Items, Total | -109.435 | -53.281 | -266.839 | 103.611 | 90.655 | 1254.52 |
| Cash From Financing Activities | 169.778 | 285.11 | 546.024 | 289.611 | 261.518 | -765.768 |
| Financing Cash Flow Items | -0.23 | 0.638 | -0.391 | 0 | 250.537 | 0 |
| Issuance (Retirement) of Stock, Net | 170.008 | 284.472 | 546.415 | 289.724 | 11.317 | -765.19 |
| Net Change in Cash | 88.99 | -58.03 | -32.222 | 10.429 | 46.505 | 75.69 |
| Issuance (Retirement) of Debt, Net | -0.113 | -0.336 | -0.578 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1874.32 | 1788.11 | 1699.34 | 1604.71 | -94.774 |
| Cash From Operating Activities | -120.749 | -238.043 | -323.227 | -407.32 | -97.735 |
| Cash From Operating Activities | 2.479 | 4.829 | 7.038 | 9.24 | 2.478 |
| Non-Cash Items | -1976.79 | -2002.66 | -1992.05 | -1984.45 | 19.096 |
| Changes in Working Capital | -20.763 | -28.324 | -37.558 | -36.822 | -24.535 |
| Cash From Investing Activities | 1874.08 | 1575.93 | 1343.2 | 1248.78 | -26.573 |
| Capital Expenditures | -1.012 | -1.261 | -1.239 | -5.741 | -2.804 |
| Other Investing Cash Flow Items, Total | 1875.09 | 1577.19 | 1344.44 | 1254.52 | -23.769 |
| Cash From Financing Activities | 7.261 | -496.197 | -747.182 | -765.768 | 1.208 |
| Issuance (Retirement) of Stock, Net | 7.347 | -496.027 | -746.409 | -765.19 | 1.289 |
| Issuance (Retirement) of Debt, Net | -0.086 | -0.17 | -0.773 | -0.578 | -0.081 |
| Net Change in Cash | 1760.59 | 841.688 | 272.788 | 75.69 | -123.1 |
| Financing Cash Flow Items | 0 | 0 | 0 | 0 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group 427000+
Traders
71000+
Active clients monthly
$46000000+
Monthly investing volume
$17000000+
Try now Withdrawn each month
Agios Pharmaceuticals, Inc. Company profile
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of a- and b-thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD and anemia associated with low-to intermediate-risk myelodysplastic syndrome (L-IR MDS), which is in Phase I clinical study.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Agios Pharmaceuticals Inc revenues was not reported. Net loss before extraordinary items increased 8% to $356.5M. Higher net loss reflects Research and development increase of 20% to $232.4M (expense), General and administrative increase of 15% to $92.5M (expense), Interest Income decrease of 87% to $836K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$4.77 to -$5.90.
Equity composition
Common Stock $.001 Par, Shares auth and O/s after the offering: 78.3 M auth., 29,380,399 issd. Insider Owns approx.38.04%.(After the IPO) IPO:TBA.
| Industry: | Bio Therapeutic Drugs |
88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
Income statement
News
The Palantir revenue outlook has an upside: here’s why
The Palantir revenue outlook slid this week, but key comments by executives of the enigmatic data software firm point to quiet confidence in a comeback
15:59, 12 August 2022
Oil trading: Asian punters book crude profits amid uncertainty
Conflicting demand forecasts by IEA, OPEC shows uncertainty’s destabilising the market
15:37, 12 August 2022
India says no pressure on it to limit energy purchases from Russia
India said on Friday there was no pressure on it from Western countries or anywhere else over its energy purchases from Russia, as Indian firms step up imports of oil and coal from that country
14:59, 12 August 2022
Forex market trends and forecasts in 5 charts: EUR/USD, GBP/USD, USD/JPY, USD/CHF and AUD/USD – August 2022 update
The US dollar's bullish trend is showing some signs of uncertainty in August 2022, as the US inflation rate softened more than expected in July, prompting markets to discount a less hawkish Fed.
13:43, 12 August 2022
Activision Blizzard stock price remains below Microsoft’s $95 a share takeover offer despite ATVI revenue beat
ATVI reported its earnings last week and its stock price is below MSFT $95 a share takeover bid.
13:21, 12 August 2022People Also Watch
US Crude Oil Spot
91.73 Price
| Long position overnight fee | 0.0138% |
| Short position overnight fee | -0.0310% |
| Overnight fee time | 21:00 (UTC) |
| Spread | 0.03 |
Trade now
Still looking for a broker you can trust?
Join the 427.000+ traders worldwide that chose to trade with Capital.com
